




FIG. 1

Binding of anti - Factor Bb mAbs

Clone	Binding to Factor Bb (EC ₅₀ , M)
M4	8.735e-010
M10	3.345e-010
M12	7.612e-010
M17	3.140e-009
M18	3.360e-010
M20	5.461e-010

FIG. 2




FIG. 3

Specificity of Binding to Factor B versus Factor Bb

Anti-Factor Bb Clone	Ratio OD fBb/fB (ELISA)	Binding to Factor B in Solution (SEC)
M4	00.59	+
M10	05.49	-
M12	00.82	+
M17	70.66	-
M18	08.40	-
M20	00.50	+

FIG. 4

Binding of anti - Factor Bb mAbs to Cyno Factor B
and Factor Bb

Binding Affinity (M)					
	M10	M12	M14	M17	M20
Factor B	3.493E-09	5.563E-09	7.813E-09	Not detected	2.551E-08
Factor Bb	4.88E-10	2.554E-09	2.503E-09	~ 2.639e-009	7.163E-08

FIG. 5




FIG. 6




FIG. 7

Inhibition of AP - Mediated C3b Deposition
on Rabbit RBC by anti - Factor Bb Monoclonal
Antibodies




FIG. 8

Inhibition of Complement AP Activity by
anti - Factor Bb Monoclonal Antibodies

Clone	Wieslab AP (IC ₅₀ , M)	AP Hemolysis (IC ₅₀ , M)	C3b Deposition (IC ₅₀ , M)
M4	6.090E-008	1.32E-08	1.4E-08
M10	2.287E-007	3.84E-08	7.78E-08
M12	5.550E-008	1.17E-08	1.22E-08
M17	~ 7.706E-007	4.34E-08	1.2E-07
M18	2.258E-007	3.96E-08	7.68E-08
M20	1.417E-007	3.19E-08	5.41E-08

FIG. 9

Inhibition of Cyno Complement AP Activity by
anti - Factor Bb Monoclonal Antibodies




FIG. 10




FIG. 11

Table 1: Anti-Factor Bb Antibody Sequences

Antibody	CDR-1	CDR-2	CDR-3	V Region
M10 VL	SEQ ID NO: 1	SEQ ID NO: 2	SEQ ID NO: 3	SEQ ID NO: 7
	QDVGTA	WAS	HQHSSNPLT	DIVMTQSHKFMSTSVGDRVSITCKA
				SQDVGTAVAWYQQKPGQSPKLLIYW
				ASTRHTGVDPDRFTGSGSGTDFTLTI
				TNVQSEDLAVYFCHQHSSNPLTFGA
M10 VH	SEQ ID NO: 4	SEQ ID NO: 5	SEQ ID NO: 6	SEQ ID NO: 8
	GTTFSNYA	ISNRGSYT	ARERPMDY	EVQLVESGGALVKPGGSLKLSCAAS
				GTTFSNYAMSWVRQTPEKRLEWVAT
				ISNRGSYTYYPDSVKGRFTISRDNA
				KNTLYLQMSSLSRSEDALYYCARER
				PMDYWGQGTSTVTVSS

FIG. 12A

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M4 VL	SEQ ID NO: 9 KSLHNSGITY	SEQ ID NO: 10 RMS	SEQ ID NO: 11 AQM LERPWT	SEQ ID NO: 15 DIVMTQAAFSNPVTLTGTSASISCSS
				SKSLHNSGITYLYWYLQRPQGSPQ
				LLIYRMSNLASGVDPDRFSGSGGTD
				FTLRISRVEAEDVGVIYCAQMLERP
				WTFGGGTKLEIK
M4 VH	SEQ ID NO: 12 GYSFTDYL	SEQ ID NO: 13 INPYNGDA	SEQ ID NO: 14 ARLENDYGFTY	SEQ ID NO: 16 EVQLQQSGPELVKPGASVKMSCKAS
				GYSFTDYLNNVVKQSHGKSLEWIGR
				INPYNGDAFYNQRFKQKATLTVDKS
				SSTAHEMLRSLTSEDSALYYCARLE
				NDYGFTYWGQGTLVTVSA

FIG. 12B

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M20 VL	SEQ ID NO: 17 QGNNY	SEQ ID NO: 18 YTS	SEQ ID NO: 19 QQHSKLPWT	SEQ ID NO: 23
				THYRASSGINAEYMGDRVTISCSA
				SQGINNYLNWYQQKPDGTVKLLIYY
				TSSLHSGVPSRFSGSGGTDYSLTI
				SNLEPEDVATYYCQQHSHKLPWTFGG GTKLEIK
M20 VH	SEQ ID NO: 20 GFSLSLTFGLG	SEQ ID NO: 21 IWNDDK	SEQ ID NO: 22 VQIPYGSRNQFDY	SEQ ID NO: 24
				QVTLKESGPGILQPSQTLSTCSFS
				GFSLSTFGLGVGWIRQPSGKGLEWL
				ASIWNNDDKYNSDLKRRPTISRDT
				SNSQVFLKISSVDTADTATYFCVQI PYGSRNQFDYWGQGTSLTVSS

FIG. 12C

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M17 VL	SEQ ID NO: 25	SEQ ID NO: 2	SEQ ID NO: 26	SEQ ID NO: 30
	QDVGSA	WAS	QQYSSYPYT	DIVMTPSHKFMSTSVGDRVSI TCKA
				SQDVGSAAVAYQQKPGHSPKLLIFW
				ASTRHIGVPDRFTGSGGTDFTLTI
				SNVQSEDLADYFCQQYSSYPYTFEGG
M17 VH	SEQ ID NO: 27	SEQ ID NO: 28	SEQ ID NO: 29	SEQ ID NO: 31
	GFTEFNFA	ISNGGGYT	ARIYYGSSYEDWFAY	EVQLVESGGVLVKPGGSLKLSCAAS
				GFTEFNFAMSWVRQTPAKRLEWVAT
				ISNGGGYTYYPDSVQGRFTISRDN
				NNTLYLQMSSLRSEDTALYYCARIY
				YGSSYEDWFAYWGQGTLLVTVSA

FIG. 12D

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M18 VL (has the same sequence as M10 VL)	SEQ ID NO: 1 QDVGTA	SEQ ID NO: 2 WAS	SEQ ID NO: 3 HQHSSNPLT	SEQ ID NO: 7 DIVMTQSHKFMSTSVGDRVSI TCKA SQDVGTAVAWYQQKPGQSPKLLIYW ASTRHTGVDPDRFTGTSGSGTDFLTIT TNVQSEDLAVYFCHQHSSNPLTFGA GTKLELK
M18 VH (has the same sequence as M10 VH)	SEQ ID NO: 4 GTFFSNYA	SEQ ID NO: 5 ISNRGSYT	SEQ ID NO: 6 ARERPM DY	SEQ ID NO: 8 EVQLVESGGALVKPGGSLKLS CAAS GTFFSNYAMSWVRQTP EKRLIEWVAT ISNRGSYTYYPDSVKGRFTISR DNA KNTLYLQMSSLRSEDTALYYCARE R PMDYWGQGTSVTVSS

FIG. 12E

Table 1, continued

Antibody	CDR-1	CDR-2	CDR-3	V Region
M12 VL (has the same sequence as M4 VL)	SEQ ID NO: 9 KSLHLSNGITY	SEQ ID NO: 10 RMS	SEQ ID NO: 11 AQLERPWT	SEQ ID NO: 15 DIVMTQAAFSNPVTIGTSASISCS SKSLHLSNGITYLYWYLQRPQSPQ LLIYRMSNLASGVDRFSCSGSTD FTLRISRVEAEDVGYYCAQMLERP WTFGGGKLEIK
M12 VH (has the same sequence as M4 VL)	SEQ ID NO: 12 GYSFTDYL	SEQ ID NO: 13 INPYNGDA	SEQ ID NO: 14 ARLENDYGFTY	SEQ ID NO: 16 EVQLQQSGPELVKPGASVKMSCKAS GYSFTDYLMMNVVKQSHGKSLEWIGR INPYNGDAFYNQRFKCKATLTVDKS SSTAHEMLRSLTSEDSALYYCARLE NDYGFTYWGQGTLVTVSA

IMGT numbering system was used to identify the CDR's (ref. Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003)).

FIG. 12F

FIG. 13

Factor Bb

1 **msgnlsqqlc lmpfilglls ggvt**tpwsl arpqqscsle gveikggsfr llqegqaley
61 vcpsgfypyp vqtrtcrstg swstlktqdq ktvrkaecra ihcprphdfe ngeywprspy
121 ynvsdeisfh cydgytlrgs anrtcqngvr wsgqtaicdn gagycsnpgi pigtrkvgsq
181 yrledsvtyh csrgltlrgs qrrtcqeggs wsgtepccqd sfmydtpqev aeafsslte
241 tiegvdaedg hgpgeqqkrk ivldpsgsmn iylvldgsds igasnftgak kclvnliekv
301 asygvkpryg lvtatyarki wkvseadss nadwvtkqln einyedhklk sgtntkkalq
361 avysmmswpd dvppegnrt rhviilmtdg lhnmggdpit videirdlly igkdrknpre
421 dyladvyfvfgv gplvnqvnin alaskkdneg hvfkvkdmen ledvfymid esqslslcgm
481 vwehrkgt dy hkqpwqakis virpskghes cmgavvseyf vltaahcftv ddkehsikvs
541 vggekrdlei evvlfhpnyn ingkkeagip efydydvali klknklkygq tirpiclpct
601 egttralrlp ptttcqqqke ellpaqdika lfvseeekkl trkevyyikng dkkgsccerda
661 qyapgydkvk di sevtprf lctggvspy dntcrgdsq gpplivhkrsr fiqvgviswg
721 vdvcknqkr qkvpahard fhinlfqvlp wlkeklqded lgfl

FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20






FIG. 21

C3 Levels in chimeric M10 Treated Monkeys



C3 Levels in chimeric M4 Treated Monkeys







FIG. 23

+M4
antibody

No CD55 added



+M4
antibody

CD55 added

